Martin Bach
Chief Operating Officer bei INVITROCUE LIMITED
Profil
Martin Bach is currently working as Vice President-Operations at Invitrocue Ltd.
and Invitrocue Pte Ltd.
He holds a Master's degree in Business Administration from Duale Hochschule Baden-Württemberg Villingen-Schwenningen.
Aktive Positionen von Martin Bach
Unternehmen | Position | Beginn |
---|---|---|
INVITROCUE LIMITED | Chief Operating Officer | 01.05.2016 |
Invitrocue Pte Ltd.
Invitrocue Pte Ltd. BiotechnologyHealth Technology Invitrocue Pte Ltd. provides products and services in the fields of in vitro drug metabolism and pharmacokinetics (DMPK), in vitro toxicology, and digital pathology utilizing cell-based models and image analytics. It also offers realms of drug testing and research and development of cosmeceuticals and medical devices solutions. The firm’s technology also provides cuepath platform, web-based platform, view share, manage, and analyze virtual slides and information. The company was founded by Steven Fang in 2012 and is headquartered in Singapore. | Chief Operating Officer | - |
Ausbildung von Martin Bach
Duale Hochschule Baden-Württemberg Villingen-Schwenningen | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 2 |
---|---|
Invitrocue Ltd.
Invitrocue Ltd. Medical/Nursing ServicesHealth Services Invitrocue Ltd. engages in the provision of bio analytic solutions including in vitro cell-based testing technologies and image analytics software for use in digital pathology. The firm focuses on the commercialization of its bio analytics services using cell based model and imaging based technology. The company was founded by Steven Fang Boon Sing and Hanry Yu in 2012 and is headquartered in Sydney, Australia. | Health Services |
Invitrocue Pte Ltd.
Invitrocue Pte Ltd. BiotechnologyHealth Technology Invitrocue Pte Ltd. provides products and services in the fields of in vitro drug metabolism and pharmacokinetics (DMPK), in vitro toxicology, and digital pathology utilizing cell-based models and image analytics. It also offers realms of drug testing and research and development of cosmeceuticals and medical devices solutions. The firm’s technology also provides cuepath platform, web-based platform, view share, manage, and analyze virtual slides and information. The company was founded by Steven Fang in 2012 and is headquartered in Singapore. | Health Technology |